KRAS and colorectal carcinoma: In a separate study, the combination of sotorasib or ARS-1620 (a G12C inhibitor with similar ligand structure), with a variety of RTK pathway inhibitors such as SHP099, erlotinib, afatinib, crizotinib, or BGJ398, all showed synergistic effects against KRAS G12C CRC cell lines and xenografts [123].